Thibault Jonckheere, CEO of Exothera, commented, "The market potential for RNA therapies continues to grow and expand into new therapeutic areas, but the process of developing a new RNA vaccine or therapeutic is hindered by outdated technology that was never intended to scale for commercialisation. We are thrilled to not only announce the launch of our new business unit focused on nucleic acids, but also our strategic collaboration with Quantoom Biosciences. This collaboration enables Exothera to make the highest quality RNA for vaccines and therapeutics with low-risk process development and almost guaranteed product quality from sequence up to mass production in a much shorter time than previously possible."
"We're thrilled by this new partnership which marks a new milestone for Quantoom," added José Castillo, CEO of Quantoom. "The advantages of continuous manufacturing for RNA are clear, and we believe this partnership will provide significant benefits to biotech and pharma companies developing RNA vaccines and therapeutics. By combining Exothera's expertise with our cutting-edge platform, we can simplify the process and accelerate timelines for RNA development and production. We're excited to see the impact this partnership will have on the industry and ultimately, on patients' lives."
Exothera’s services will be available to biotech and pharmaceutical companies of all sizes and stages of development whether they are starting from a known protein sequence (antigen) or have a product in pre-clinical development or clinical trials. The company is currently accepting inquiries for its services and is actively seeking partnerships with biotech and pharmaceutical companies to support their drug development programmes.About Exothera
Exothera is a contract research, development, and manufacturing organisation (CRDMO) dedicated to viral vector and nucleic acids production. As a technology-driven company, Exothera provides best-in-class bioprocessing expertise that capitalises on the best and most innovative manufacturing technologies developed within the Univercells group. The company delivers accelerated discovery services and process development/optimisation to rapidly reach GMP clinical and commercial production of viral vectors and nucleic acids. The mission of Exothera and Univercells is to make life-changing therapies available to all. Visit: www.exothera.world
.About Quantoom Biosciences
Quantoom Biosciences is reinventing mRNA production by developing an RNA Platform (Nfinity) that encompasses DNA (Nplify) and RNA (Ntensify) manufacturing and formulation (Ncapsulate), along with critical reagent supply, from sequence to large scale production. We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology. Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem. We are part of Univercells, a global life sciences group that makes biologics available to all. Visit: www.quantoom.com